218 related articles for article (PubMed ID: 32623652)
1. A case of cryopyrin-associated periodic fever syndrome during canakinumab administration complicated by inflammatory bowel disease.
Yamasaki Y; Kubota T; Takei S; Imanaka H; Nonaka Y; Kawano Y
Clin Rheumatol; 2021 Jan; 40(1):393-397. PubMed ID: 32623652
[TBL] [Abstract][Full Text] [Related]
2. Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene.
Iida Y; Wakiguchi H; Okazaki F; Nakamura T; Yasudo H; Kubo M; Sugahara K; Yamashita H; Suehiro Y; Okayama N; Hashimoto K; Iwamoto N; Kawakami A; Aoki Y; Takada H; Ohga S; Hasegawa S
Clin Rheumatol; 2019 Mar; 38(3):943-948. PubMed ID: 30338413
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
4. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.
Hui A; Johnson LB; Greemberg R; Penney L; Ramsey SE
Int J Pediatr Otorhinolaryngol; 2019 May; 120():68-72. PubMed ID: 30772614
[TBL] [Abstract][Full Text] [Related]
5. Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report.
Zayaeva AA; Sokolova LV; Shaduro DV; Petrov AV; Kulanthaivel S; Kaliberdenko VB
Curr Rheumatol Rev; 2022; 18(4):373-379. PubMed ID: 34784874
[TBL] [Abstract][Full Text] [Related]
6. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T; Izawa K; Masui S; Yamazaki A; Yamasaki Y; Matsubayashi T; Shiraki M; Ohnishi H; Yasumura J; Kawabe T; Miyamae T; Matsubara T; Arakawa N; Ishige T; Takizawa T; Shimbo A; Shimizu M; Kimura N; Maeda Y; Maruyama Y; Shigemura T; Furuta J; Sato S; Tanaka H; Izumikawa M; Yamamura M; Hasegawa T; Kaneko H; Nakagishi Y; Nakano N; Iida Y; Nakamura T; Wakiguchi H; Hoshina T; Kawai T; Murakami K; Akizuki S; Morinobu A; Ohmura K; Eguchi K; Sonoda M; Ishimura M; Furuno K; Kashiwado M; Mori M; Kawahata K; Hayama K; Shimoyama K; Sasaki N; Ito T; Umebayashi H; Omori T; Nakamichi S; Dohmoto T; Hasegawa Y; Kawashima H; Watanabe S; Taguchi Y; Nakaseko H; Iwata N; Kohno H; Ando T; Ito Y; Kataoka Y; Saeki T; Kaneko U; Murase A; Hattori S; Nozawa T; Nishimura K; Nakano R; Watanabe M; Yashiro M; Nakamura T; Komai T; Kato K; Honda Y; Hiejima E; Yonezawa A; Bessho K; Okada S; Ohara O; Takita J; Yasumi T; Nishikomori R;
Arthritis Rheumatol; 2024 Jun; 76(6):949-962. PubMed ID: 38268504
[TBL] [Abstract][Full Text] [Related]
8. Neurology of the cryopyrin-associated periodic fever syndrome.
Parker T; Keddie S; Kidd D; Lane T; Maviki M; Hawkins PN; Lachmann HJ; Ginsberg L
Eur J Neurol; 2016 Jul; 23(7):1145-51. PubMed ID: 26931528
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
12. Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System.
Keddie S; Parker T; Lachmann HJ; Ginsberg L
Curr Treat Options Neurol; 2018 Sep; 20(10):43. PubMed ID: 30175395
[TBL] [Abstract][Full Text] [Related]
13. Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
Mueller SM; Itin P; Haeusermann P
Dermatology; 2011; 223(2):113-8. PubMed ID: 21967869
[TBL] [Abstract][Full Text] [Related]
14. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
15. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
16. Neurologic manifestations of the cryopyrin-associated periodic syndrome.
Kitley JL; Lachmann HJ; Pinto A; Ginsberg L
Neurology; 2010 Apr; 74(16):1267-70. PubMed ID: 20404307
[TBL] [Abstract][Full Text] [Related]
17. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
[TBL] [Abstract][Full Text] [Related]
18. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
19. Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome.
Elmi AA; Wynne K; Cheng IL; Eleftheriou D; Lachmann HJ; Hawkins PN; Brogan P
Pediatr Rheumatol Online J; 2019 Jul; 17(1):36. PubMed ID: 31287007
[TBL] [Abstract][Full Text] [Related]
20. Cryopyrin-associated periodic syndromes: diagnosis and management.
Miyamae T
Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
